15. A pharmaceutical composition comprising the bispecific construct according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier.

16. Use of a ~~The~~ bispecific construct according to any one of claims 2 to 10 ~~for use~~ in the manufacture of a medicament for the treatment of an inflammatory and/or autoimmune disease, particularly in the treatment of a human patient, particularly wherein the inflammatory and/or autoimmune disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, juvenile diabetes, autoimmune uveitis, and multiple sclerosis, Parkinson´s disease, Alzheimer´s disease, and ischemia-reperfusion injury.

17. Use of a ~~The~~ bispecific construct according to claim 1 ~~for use~~ in the manufacture of a medicament for treatment of a human patient, particularly wherein the cancer is selected from the group consisting of colorectal cancer, lung cancer, breast cancer, nasopharyngeal cancer, oral cancer, esophageal cancer, pancreatic cancer, B-cell lymphomas, and T-cell lymphomas, including adult T-cell lymphoma leukemia (ATLL), acute myeloid lymphoma (AML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), pediatric acute lymphoblastic lymphoma (B-ALL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-cell lymphoma (ALCL), T-/natural killer-cell lymphomas, and peripheral T-cell lymphoma (PTCL).

18. The bispecific construct according to claim 17, wherein said human patient is a patient, which has a high Th17 response.